Joint Clinical Trials Office

You are here

A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas

Clinical Trial Details

This clinical trial is for men and women with meningioma. Currently available treatments are not effective in treating patients with this disease. Therefore, there is a need to find treatments that work for patients with meningoioma.

This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligible patients will be randomized (by chance) to one of each arm (vismodegib or GSK2256098). There is no placebo (blank pill).  Patients will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.

Key Eligibility: 
  • Men and women age 18 and older
  • Diagnosis of meningioma
  • Open to untreated and previously treated patients
  • Detailed eligibility reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan

Contact(s)

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1609017570

ClinicalTrials.gov:

NCT02523014

Sponsor:

A071401

Status

Open to Enrollment

Age Group

Adult

Sponsor